Nofazinlimab Biosimilar – Anti-PD1 mAb – Research Grade

Description of Nofazinlimab Biosimilar - Anti-PD1 mAb - Research Grade

Nofazinlimab Biosimilar: A Revolutionary Anti-PD1 mAb for

Cancer Treatment

Nofazinlimab Biosimilar, also known as Anti-PD1 mAb, is a promising therapeutic antibody that has shown great potential in the treatment of various types of cancer. This biosimilar drug is a replica of the original Nofazinlimab antibody, which has been approved by the FDA for the treatment of melanoma, lung cancer and other solid tumors. With its unique structure and mechanism of action, Nofazinlimab Biosimilar is expected to revolutionize cancer treatment and improve patient outcomes.

Structure of Nofazinlimab Biosimilar

Nofazinlimab Biosimilar is a monoclonal antibody (mAb) that specifically targets the programmed cell death protein 1 (PD1) receptor. It is a fully humanized IgG4 antibody, meaning that it is derived from human cells and has been modified to reduce its immunogenicity. The antibody consists of two heavy chains and two light chains, connected by disulfide bonds. The variable regions of the antibody are responsible for binding to the PD1 receptor, while the constant regions determine the effector function of the antibody.

The unique structure of Nofazinlimab Biosimilar allows it to bind to the PD1 receptor with high affinity and specificity, blocking its interaction with its ligands PD-L1 and PD-L2. This prevents the inhibition of T cell function and allows for the activation of the immune system to target and destroy cancer cells.

Mechanism of Action

The PD1 receptor is a key immune checkpoint that plays a critical role in regulating the immune response.

Cancer cells often exploit this checkpoint by overexpressing PD-L1, which binds to the PD1 receptor on T cells and suppresses their activity. This results in the evasion of the immune system by cancer cells.

Nofazinlimab Biosimilar works by binding to the PD1 receptor, preventing its interaction with PD-L1 and PD-L2. This releases the brakes on the immune system, allowing T cells to recognize and attack cancer cells. Additionally, the binding of Nofazinlimab Biosimilar to the PD1 receptor triggers antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of cancer cells by immune cells.

Applications in Cancer Treatment

Nofazinlimab Biosimilar has shown promising results in clinical trials for the treatment of various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. It has also been investigated for its potential in combination with other cancer therapies, such as chemotherapy and targeted therapy.

One of the major advantages of Nofazinlimab Biosimilar is its ability to target a wide range of cancers, as the PD1 receptor is expressed on the surface of many tumor cells. This makes it a potential treatment option for patients with different types of cancer, including those that have become resistant to other therapies.

Conclusion

Nofazinlimab Biosimilar is a groundbreaking anti-PD1 mAb that has the potential to revolutionize cancer treatment. Its unique structure and mechanism of action make it a highly specific and effective therapy for a wide range of cancers. With ongoing research and clinical trials, Nofazinlimab Biosimilar is expected to become a key player in the fight against cancer and improve patient outcomes significantly.

Keywords: Nofazinlimab Biosimilar, Anti-PD1 mAb, monoclonal antibody, cancer treatment, PD1 receptor, immune checkpoint, immunotherapy, clinical trials

Nofazinlimab Biosimilar - Anti-PD1 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Nofazinlimab Biosimilar - Anti-PD1 mAb (cat. No.PX-TA1760) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450